Status:
NOT_YET_RECRUITING
Multinational Glanzmann Study
Lead Sponsor:
UMC Utrecht
Conditions:
Glanzmann Thrombasthenia
Eligibility:
All Genders
16+ years
Brief Summary
Glanzmann thrombasthenia is a rare autosomal recessive platelet disorder characterized by a lack of functional integrins alfaIIb or beta3 (glycoproteins IIb/IIIa). The prevalence is variously reported...
Eligibility Criteria
Inclusion
- Adult patients (≥16 years);
- Biochemically or genetically diagnosed Glanzmann thrombasthenia.
- Willing and able to give written informed consent.
Exclusion
- Patients with acquired thrombasthenic states caused by auto-immune disorders or drugs.
Key Trial Info
Start Date :
March 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2029
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06204042
Start Date
March 1 2024
End Date
March 1 2029
Last Update
February 28 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.